1: N Engl J Med. 2008 Jun 12;358(24):2545-59. Epub 2008 Jun 6.Click here to read Links
Comment in:
ACP J Club. 2008 Sep 16;149(3):6-7.
Am J Kidney Dis. 2009 Jan;53(1):12-5.
Curr Diab Rep. 2009 Feb;9(1):7-8.
Evid Based Med. 2008 Dec;13(6):168-9.
Evid Based Nurs. 2009 Jan;12(1):12-3.
Kardiol Pol. 2008 Sep;66(9):1013-7; discussion 1017-9.
N Engl J Med. 2008 Jun 12;358(24):2537-9.
N Engl J Med. 2008 Jun 12;358(24):2630-3.
N Engl J Med. 2008 Jun 12;358(24):2633-5.
N Engl J Med. 2008 Oct 2;359(14):1519-20; author reply 1520-1.
N Engl J Med. 2008 Oct 2;359(14):1519; author reply 1520-1.
N Engl J Med. 2008 Oct 2;359(14):1520; author reply 1520-1.
Nat Clin Pract Endocrinol Metab. 2009 Jan;5(1):8-9.
Prev Cardiol. 2008 Fall;11(4):230-6.

Effects of intensive glucose lowering in type 2 diabetes.

BACKGROUND: Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. METHODS: In this randomized study, 10,251 patients (mean age, 62.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. RESULTS: At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001). CONCLUSIONS: As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.) 2008 Massachusetts Medical Society

PMID: 18539917 [PubMed - indexed for MEDLINE]